Results 11 to 20 of about 51,423 (237)

Evidence of comparative efficacy should have a formal role in European drug approvals [PDF]

open access: yes, 2011
Despite methodological concerns, comparative efficacy evidence should be required at the time of drug approval, says Corinna Sorenson and colleagues, to allow patients, clinicians, and other healthcare decision makers to determine whether a new drug is ...
Cylus, Jonathan   +3 more
core   +1 more source

WHAT IS THERAPEUTIC EQUIVALENCE OF GENERIC DRUG AND HOW TO PROVE IT

open access: yesРациональная фармакотерапия в кардиологии, 2016
The problem of generic drugs use in clinical practice and confirmation of their therapeutic equivalence is discussed. The significance of studies on generic drugs bioequivalence, as well as details of international practice and regulations in this area ...
N. P. Kutishenko   +2 more
doaj   +1 more source

PROBLEM OF GENERIC REPLACEMENT: ADVANTAGES AND DISADVANTAGES

open access: yesРациональная фармакотерапия в кардиологии, 2016
The main differences between original and generic drugs as well as registration criteria for generics are described. Possible reasons of discrepancy in bioequivalence and therapeutic equivalence of original and generic drugs are reviewed. The examples of
S. N. Tolpygina, S. Yu. Martsevich
doaj   +3 more sources

VALUE OF THERAPEUTIC EQUIVALENCE IN SUBSTITUTION OF ORIGINAL DRUG WITH GENERIC BY EXAMPLE OF FOSINIPRIL

open access: yesРациональная фармакотерапия в кардиологии, 2016
Aim. To study the therapeutic equivalence of original and generic fosinopril in patients with arterial hypertension (HT) of 1-2 degrees, and to evaluate the cost effectiveness of original drug substitution with generic. Material and methods.
N. P. Kutishenko   +3 more
doaj   +1 more source

Efficacy and Patient-Reported Outcomes of a New Mometasone Cream Treating Atopic Eczema [PDF]

open access: yes, 2012
This double-blind controlled phase II study was conducted to compare a newly developed formulation of mometasone furoate with a water content of 33% (Monovo (R) Cream) and with a smooth consistency versus the commercially available fatty cream of ...
Ruzicka, Thomas   +2 more
core   +1 more source

ДЖЕНЕРИЧЕСКИЕ СТАТИНЫ В КЛИНИЧЕСКОЙ ПРАКТИКЕ: ДЕШЕВЫЕ ЗАМЕНИТЕЛИ ИЛИ ДОСТОЙНАЯ АЛЬТЕРНАТИВА БРЕНДАМ. АТОРВАСТАТИН

open access: yesАрхивъ внутренней медицины, 2012
The relevance of cardiovascular disease in the world and in Russia causes including calls for patient compliance with medical recommendations. Compliance, in turn, depends on the cost of medicines. From an economic point of view generic drugs appear in a
В. П. Михин   +1 more
doaj   +1 more source

New Anticonvulsants: Interchangeability Issues and the Use of Generic Anticonvulsants in Clinical Practice

open access: yesРегуляторные исследования и экспертиза лекарственных средств, 2019
This article looks into interchangeability and therapeutic equivalence of innovator and generic anticonvulsants — the first-generation and new antiepileptic drugs (AEDs).
V. V. Arkhipov   +4 more
doaj   +1 more source

Guidelines for the recording and evaluation of pharmaco-EEG data in man: the International Pharmaco-EEG Society (IPEG) [PDF]

open access: yes, 2012
The International Pharmaco-EEG Society (IPEG) presents updated guidelines summarising the requirements for the recording and computerised evaluation of pharmaco-EEG data in man.
BABILONI, CLAUDIO   +24 more
core   +1 more source

PREDICTION OF THE INFLUENCE OF ORIGINAL AND GENERIC ROSUVASTATIN ON DIRECT MEDICAL COSTS OF SECONDARY PREVENTION IN PATIENTS WITH CHRONIC TYPES OF ISCHEMIC HEART DISEASE

open access: yesКардиоваскулярная терапия и профилактика, 2015
Aim. To study therapeutic equivalence of rosuvastatin generic and original medication and to conduct the pharmacoeconomic analysis to compare the impact of the drug on direct expenses in secondary prevention for the patients with chronic ischemic heart ...
E. I. Tarlovskaya   +3 more
doaj   +1 more source

Safety of Use of Russian Biosimilars of Interferon Beta-1b in the Treatment of Multiple Sclerosis: a Meta-analysis of Original Studies

open access: yesБезопасность и риск фармакотерапии, 2019
Presently, an active search for  modern drugs for  the  treatment of multiple sclerosis is ongoing. Since  the  treatment with original drugs is expensive, therefore, the  development of local biosimilars is underway, which at a lower  cost should be ...
D. O. Gudz   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy